Revenues (Tables)

6 Months Ended

Jun. 30, 2019

Revenues by product are summarized as follows:



	For the Three Months Ended June 30,
(In millions)	2019						2018
	United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis (MS):
TECFIDERA	$	869.8	$	280.4	$	1,150.2	$	825.8	$	261.0	$	1,086.8
Interferon*	379.7		174.7		554.4		444.7		180.8		625.5
TYSABRI	264.3		211.0		475.3		265.5		201.7		467.2
FAMPYRA	—		24.1		24.1		—		23.0		23.0
Subtotal: MS product revenues	1,513.8		690.2		2,204.0		1,536.0		666.5		2,202.5

Spinal Muscular Atrophy:
SPINRAZA	230.6		257.6		488.2		205.9		216.8		422.7

Biosimilars:
BENEPALI	—		120.3		120.3		—		115.6		115.6
IMRALDI	—		47.3		47.3		—		—		—
FLIXABI	—		16.8		16.8		—		11.2		11.2
Subtotal: Biosimilar product revenues	—		184.4		184.4		—		126.8		126.8

Other:
FUMADERM	—		3.7		3.7		—		5.5		5.5
Total product revenues	$	1,744.4	$	1,135.9	$	2,880.3	$	1,741.9	$	1,015.6	$	2,757.5

*Interferon includes AVONEX and PLEGRIDY.



	For the Six Months Ended June 30,
(In millions)	2019						2018
	United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis (MS):
TECFIDERA	$	1,587.5	$	561.5	$	2,149.0	$	1,554.7	$	519.0	$	2,073.7
Interferon*	707.0		348.3		1,055.3		816.0		359.8		1,175.8
TYSABRI	509.3		426.4		935.7		515.2		414.1		929.3
FAMPYRA	—		47.0		47.0		—		47.4		47.4
ZINBRYTA	—		—		—		—		1.4		1.4
Subtotal: MS product revenues	2,803.8		1,383.2		4,187.0		2,885.9		1,341.7		4,227.6

Spinal Muscular Atrophy:
SPINRAZA	453.9		552.8		1,006.7		393.9		392.7		786.6

Biosimilars:
BENEPALI	—		244.3		244.3		—		236.5		236.5
IMRALDI	—		83.0		83.0		—		—		—
FLIXABI	—		31.5		31.5		—		17.8		17.8
Subtotal: Biosimilar product revenues	—		358.8		358.8		—		254.3		254.3

Other:
FUMADERM	—		7.8		7.8		—		12.5		12.5
Total product revenues	$	3,257.7	$	2,302.6	$	5,560.3	$	3,279.8	$	2,001.2	$	5,281.0

*Interferon includes AVONEX and PLEGRIDY.

An analysis of the change in reserves for discounts and allowances is summarized as follows:



(In millions)	Discounts			Contractual Adjustments			Returns			Total
Balance, as of December 31, 2018	$	127.8		$	888.8		$	34.7		$	1,051.3
Current provisions relating to sales in current year	308.8			1,391.0			10.6			1,710.4
Adjustments relating to prior years	(0.4		)	(41.9		)	(0.1		)	(42.4		)
Payments/credits relating to sales in current year	(189.6		)	(827.6		)	(0.6		)	(1,017.8		)
Payments/credits relating to sales in prior years	(121.9		)	(505.2		)	(11.9		)	(639.0		)
Balance, as of June 30, 2019	$	124.7		$	905.1		$	32.7		$	1,062.5

The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:



(In millions)	As of June 30, 2019		As of December 31, 2018
Reduction of accounts receivable, net	$	199.0	$	176.6
Component of accrued expenses and other	863.5		874.7
Total revenue-related reserves	$	1,062.5	$	1,051.3

Revenues from anti-CD20 therapeutic programs are summarized as follows:



	For the Three Months Ended June 30,				For the Six Months Ended June 30,
(In millions)	2019		2018		2019		2018
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA	$	377.2	$	359.0	$	768.0	$	708.6
Other revenues from anti-CD20 therapeutic programs	199.2		131.4		325.8		225.0
Total revenues from anti-CD20 therapeutic programs	$	576.4	$	490.4	$	1,093.8	$	933.6

Other revenues are summarized as follows:



	For the Three Months Ended June 30,						For the Six Months Ended June 30,
(In millions)	2019			2018			2019			2018
Revenues from collaborative and other relationships:
(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie	$	(0.1	)	$	(2.5	)	$	(0.5	)	$	(7.2	)
Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis	52.2			14.7			77.0			32.6
Other royalty and corporate revenues:
Royalty	2.7			17.3			6.6			27.9
Other corporate	105.2			79.1			369.3			219.7
Total other revenues	$	160.0		$	108.6		$	452.4		$	273.0